摘要
目的:探讨奥沙利铂不同给药方式治疗复发性卵巢癌的疗效及对机体免疫状态、远期生存率的影响。方法:116例晚期复发性卵巢癌患者,随机数表法分为静脉给药组、腹腔热灌注组,每组58例。静脉给药组患者接受多西他赛联合奥沙利铂静脉给药,腹腔热灌注组患者接受多西他赛联合奥沙利铂腹腔热灌注给药,治疗3个疗程后评估疗效并记录药物相关不良反应发生情况,随访2年远期生存情况。结果:化疗后,腹腔热灌注组的治疗有效率高于静脉给药组;血清中糖类抗原125(CA125)、人附睾蛋白4(HE4)、骨桥蛋白(OPN)的水平低于静脉给药组;外周血中CD3^+、CD4^+T淋巴细胞分布比例及CD4^+/CD8^+比值高于静脉给药组,CD8^+T淋巴细胞分布比例低于静脉给药组(P>0.05)。化疗期间,腹腔热灌注组患者的胃肠道反应、骨髓抑制发生率低于静脉给药组(P<0.05)。随访发现,腹腔热灌注组患者的1年生存率高于静脉给药组患者,平均生存时间长于静脉给药组患者(P<0.05)。两组患者的2年生存率差异无统计学意义(P>0.05)。结论:奥沙利铂腹腔热灌注用药可有效提升复发性卵巢癌患者的近期疗效,且在延长其生存时间方面也有一定作用。
Objective:To investigate the efficacy of different administration modes of oxaliplatin in the treatment of recurrent ovarian cancer and its influence on immune status and long-term survival rate.Methods:116 cases of advanced recurrent ovarian cancer patients were chosen as research subject,they were randomly divided into intravenous administration group and intraperitoneal hyperthermia perfusion group,each with 58 cases.Patients in intravenous group were treated with docetaxel combined with oxaliplatin intravenously,those in intraperitoneal hyperthermia group were treated with docetaxel combined with oxaliplatin intraperitoneal hyperthermia.After three courses of treatment,curative effect was evaluated and the occurrence of drug-related adverse reactions was recorded.The long-term survival was recorded after two years follow-up.Results:After chemotherapy,the therapeutic efficiency of intraperitoneal hyperthermia perfusion group was higher than that of intravenous administration group,serum levels of CA125,HE4 and OPN were lower than those of intravenous administration group,the distribution ratio of CD3^+,CD4^+T lymphocyte and CD4^+/CD8^+ratio in peripheral blood were higher than those of intravenous administration group,and the distribution ratio of CD8^+T lymphocyte was lower than that of intravenous administration group(P>0.05).During chemotherapy,the incidence of gastrointestinal reactions and bone marrow suppression in abdominal hyperthermic perfusion group were lower than that in intravenous administration group(P<0.05).Follow-up results showed that the 1-year survival rate of intraperitoneal hyperthermic perfusion group was higher than that of intravenous group,and average survival time was longer than that of intravenous group(P<0.05).There was no significant difference in 2-year survival rate between two groups(P>0.05).Conclusion:Oxaliplatin intraperitoneal hyperthermic perfusion can effectively improve the short-term efficacy of patients with recurrent ovarian cancer and prolong their survival time.
作者
邹中华
朱忻
周俊东
曹智辉
吴锦昌
ZOU Zhong-hua;ZHU Xin;ZHOU Jun-dong;CAO Zhi-hui;WU Jin-chang(Department of Radiation Oncology,Suzhou Hospital Affiliated to Nanjing Medical University,Suzhou 215001,Jiangsu,China;Department of Dental,Suzhou Hospital Affiliated to Nanjing Medical University,Suzhou 215001,Jiangsu,China)
出处
《川北医学院学报》
CAS
2020年第1期65-68,共4页
Journal of North Sichuan Medical College
基金
江苏省苏州市肿瘤临床医学中心基金资助项目(Szzx201506)
江苏省药学会奥赛康临床药学基金(201506)。
